SC
ABBV icon

Schubert & Co’s AbbVie ABBV Stock Holding History

Schubert & Co’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236K Sell
938
-22
-2% -$4.73K 0.16% 77
2026
Q1 		$209K Sell
960
-15
-2% -$3.33K 0.17% 68
2025
Q4 		$223K Sell
975
-262
-21% -$59.7K 0.18% 63
2025
Q3 		$286K Sell
1,237
-116
-9% -$23.6K 0.21% 57
2025
Q2 		$251K Buy
1,353
+205
+18% +$38.1K 0.18% 64
2025
Q1 		$241K Buy
+1,148
New +$223K 0.16% 56
2024
Q3 		– Sell
-1,164
Closed -$212K – 67
2024
Q2 		$212K Hold
1,164
– – 0.18% 31
2024
Q1 		$212K Buy
+1,164
New +$201K 0.18% 31
2023
Q3 		– Sell
-1,517
Closed -$204K – 31
2023
Q2 		$204K Sell
1,517
-48
-3% -$7.04K 0.19% 35
2023
Q1 		$249K Sell
1,565
-407
-21% -$62.2K 0.22% 29
2022
Q4 		$319K Buy
1,972
+81
+4% +$12.4K 0.29% 20
2022
Q3 		$254K Buy
1,891
+12
+0.6% +$1.72K 0.24% 25
2022
Q2 		$288K Buy
1,879
+1,727
+1,136% +$264K 0.27% 19
2022
Q1 		$25K Buy
152
+40
+36% +$5.81K 0.03% 73
2021
Q4 		$15K Buy
+112
New +$13.2K 0.02% 81

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Schubert & Co's ABBV Position: Q2 2026 in Review

Schubert & Co reduced its AbbVie (ABBV) stake by 2.3% in Q2 2026, selling an estimated $4.73K and leaving 938 shares worth $236K. The position accounts for 0.16% of the portfolio, ranked #77.

Schubert & Co first reported a position in ABBV in Q4 2021 and has held it in 15 quarters since. The position peaked at $319K in Q4 2022. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Schubert & Co held 938 shares of AbbVie worth $236K as of Q2 2026.
  • Schubert & Co sold 22 AbbVie shares in Q2 2026, an estimated $4.73K.
  • AbbVie made up 0.16% of Schubert & Co's portfolio in Q2 2026, its #77 holding.
  • Schubert & Co first reported a position in AbbVie in Q4 2021 and has held it in 15 quarters since.
  • Schubert & Co's AbbVie position peaked at $319K in Q4 2022.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Schubert & Co's 13F filing for Q2 2026, filed 30 Jul 2026.